Efficacy, Safety and Anticancer Activity of Protein Nanoparticle-Based Delivery of Doxorubicin through Intravenous Administration in Rats

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Golla, Kishore ^a   Cherukuvada, Bhaskar ^a   Ahmed, Farhan ^a   Kondapi, Anand K ^a  

^a UNIVERSITY OF HYDERABAD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOTRANSFERRIN NANOPARTICLE; CREATININE; DOXORUBICIN; LACTOFERRIN NANOPARTICLE; NANOPARTICLE; PROTEIN P21; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA; VASCULOTROPIN RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TISSUE LEVEL; ENZYME ASSAY; HEMOLYSIS; HUMAN; LIVER CELL CARCINOMA; MALE; NONHUMAN; PARTICLE SIZE; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RAT; SINGLE DRUG DOSE; UREA NITROGEN BLOOD LEVEL;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPROTEINS; BIOLOGICAL MARKERS; BODY WEIGHT; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; DOXORUBICIN; HEMOLYSIS; LACTOFERRIN; LIVER NEOPLASMS; MALE; NANOPARTICLES; RATS; TRANSFERRIN; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 84871355748     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051960     Document Type: Article

References (53)

1. Bosch FX, Ribes J, Diaz M, Cleries R, (2004) Primary liver cancer worldwide incidence and trends. Gastroenterology 127: S5-S16.
2. Parkin DM, Bray F, Ferlay J, Pisani P, (2002) Global cancer statistics, 2002, CA CancerJ. Clin 55 (2):: 74-108.
3. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, et al. (2002) Hepatitis B e antigen and the risk of hepatocellular carcinoma. NEJM 347 (3):: 168-74.
4. Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, et al. (1989) Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 2 (8670):: 1006-1008.
5. Varela M, Real MI, Burrel M, Forner A, Sala M, et al. (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. J Hepatology 46: 474-481.
6. Thomas MB, Zhu AX, (2005) Hepatocellularcarcinoma: the need forprogress. J ClinOncol 23: 2892-9.
7. Llovet JM, Real MI, Montana X, Planas R, Coll S, et al. (2002) Barcelona Liver Cancer Group: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734-1739.
8. Okada S, Okazaki N, Nose H, Shimada Y, Yoshimori M, Aoki K, (1993) A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 50 (1):: 2-26.
9. Falkson G, Moertel CG, Lavin P, Pretorius FJ, Carbone PP, (1978) Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 42 (5):: 2149-2156.
10. Lin HL, Liu TY, Chau GY, Lui WY, Chi CW, (2000) Comparison of 2methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 89 (5):: 983-994.
11. Hamad I, Moghimi SM, (2008) Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug. ExpertOpin Drug Deliv 5: 205-219.
12. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, et al. (2002) Randomized controlled trial of transarteriallipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171.
13. Xu Z, Chen L, Gu W, Gao Y, Lin L, et al. (2009) The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 30: 226-32.
14. Bae S, Ma K, Kim TH, Lee ES, Oh KT, et al. (2011) Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials 33: 1536-1546.
15. Holmström P, Gåfvels M, Eriksson LC, Dzikaite V, Hultcrantz R, et al. (2006) Expression of iron regulatory genes in a rat model of hepatocellular carcinoma. Liver Int 26: 976-85.
16. Tseng HH, Chang JG, Hwang YH, Yeh KT, Chen YL, et al. (2009) Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications. J Cancer Res Clin Oncol 135: 1413-20.
17. Krishna ADS, Mandraju RK, Kishore G, Kondapi AK, (2009) An Efficient Targeted Drug Delivery through Apotransferrin Loaded Nanoparticles. PLoS ONE 4 (10):: e7240.
18. Morgan EH, Smith GD, Peters TJ, (1986) Uptake and subcellular processing of 59Fe-125I-labelled transferrin by rat liver. Biochem J 237: 163-173.
19. Cao H, Krueger EW, McNiven MA, (2011) Hepatocytes internalize trophic receptors at large endocytic "Hot Spots". Hepatology 54: 1819-29.
20. Fleming MD, Romano MA, Su MA, Garrick LM, Garrick MD, et al. (1998) Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. ProcNatlAcadSci U S A 95: 1148-53.
21. Zhao N, Gao J, Enns CA, Knutson MD, (2010) ZRT/IRT-like protein 14 (ZIP14) promotes the cellular assimilation of iron through transferrin. J BiolChem 285: 32141-50.
22. Cohn EJ, Strong LE, Hughes WL, Mulford DJ, Ashworth JN, et al. (1964) Preparation and Properties of Serum and Plasma Proteins. IV. A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids. J Am Chem Soc 68: 459-475.
23. Sharma AK, Paramasivam M, Srinivasan A, Yadav MP, Singh TP, (1999) Three-dimensional structure of mare diferriclactoferrin at 2.6Aresolution. J. Mol. Biol 289: 303-317.
24. Zhang J, Guang X, Chen Y, Li Y, Liu CS, (2007) Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin. Nanomedicine 3: 258-265.
25. Fiume L, Bolondi L, Busi C, Chieco P, Kratz F, et al. (2005) Doxorubicincoupled to lactosaminatedalbumininhibits the growth of hepatocellularcarcinomasinduced in rats by diethylnitrosamine. J Hepatol 43: 645-52.
26. Adams M, Buehner M, Chandrasekhar K, Ford G, Hackert M, et al. (1973) Structure-Function Relationships in Lactate Dehydrogenase,. ProcNatlAcadSci U S A 70: 1968.
27. Ursini E, Maiorino M, Gregoin C, (1985) Theselenoenzyme phospholipid hydroperoxide glutathione peroxidase. Biochem Biophys Acta 839: 62-70.
28. Borbath I, Leclercq IA, Sempoux C, Abarca-Quinones J, Desaeger C, et al. (2010) Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. ChemBiol Interact 183: 238-48.
29. Wong HL, Bendayan R, Rauth AM, Wu XY, (2006) Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release 116: 275-284.
30. Lina R, Nga LS, Wang C, (2005) In vitro study of anticancer drug doxorubicin in PLGA-based microparticles. Biomaterials 26: 4476-81.
31. Gabizon A, (2001) Pegylated liposomal doxorubicin: Metamorphosis of anold drug into a new form of chemotherapy. Cancer investigation 19: 424-36.
32. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, (1994) Prolongedcirculation time and enhanced accumulation in malignant exudatesof doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 98-992.
33. SheelaA, AbrahamDN,WaterhouseLD,Mayer PRC, Thomas DM, et al.(2003) Liposomal formulation of doxorubicin. In D. Nejat (ed.),Methods in enzymology, vol. 391. Academic press 71-97.
34. Ahmed F, Pakunlu RI, Brannan A, Bates FS, Minko T, et al. (2006) Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. J Contr Release 116: 150-8.
35. Xu JP, Ji J, Chen W, Shen J, (2005) Novel biomimetic polymersomes as polymer therapeutics for drug delivery. J Contr Release 107: 502-12.
36. Pang Z, Lu W, Gao H, Hu K, Chen J, et al. (2008) Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Contr Release 128: 120-7.
37. Upadhyay KK, Bhat AN, Mishra AK, Chutani K, Dwarakanath BS, et al. (2010) The intracellular drug delivery and antitumor activity of doxorubicin loaded poly(γ-benzyl L-glutamate)-bhyaluronanpolymersomes. Biomaterials 10: 2882-92.
38. Kataoka K, Matsumoto T, Yokoyama M, Okano T, Sakurai Y, et al. (2000) Doxorubicin-loaded poly (ethylene glycol)-poly([beta]-benzyl-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J Contr Release 64: 143-53.
39. Yooand HS, Park TG, (2001) Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Contr Release 70: 63-70.
40. Shuai X, Ai H, Nasongkla N, Kim S, Gao J, (2004) Micellar carriers based on block copolymers of poly([var epsilon]-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. J Contr Release 98: 415-26.
41. Fundarò A, Cavalli R, Bargoni A, Vighetto D, Zara GP, et al. (2000) Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res 42: 337-43.
42. Zara GP, Cavalli R, Bargoni A, Fundarò A, Vighetto D, et al. (2002) Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target 10: 327-35.
43. Al-Abd AM, Hong KY, Song SC, Kuh HJ, (2010) Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice. J Control Release 142: 101-7.
44. Schneider Y, Abarca J, Aboud-Pirak E, Baurain R, Ceulemans F, et al. (1984) Drug targeting in human cancerchemotherapy. In: Gregoriadis G, Poste G, Senior J, Trouet A, editors. Receptor-mediated targeting of drugs. NATO ASI series A: life sciences 1-25.
45. Fiume L, Bolondi L, Busi C, Chieco P, Kratz F, et al. (2005) Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine. J Hepatology 43: 645-652.
46. Yokoyama M, Fukushima S, Uehara R, Okamoto K, Kataoka K, et al. (1998) Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor. J Control Release 50: 79-92.
47. Chiannilkulchai N, Driouich Z, Benoit JP, Parodi AL, Couvreur P, (1989) Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases. Sel Cancer Ther 5: 1-11.
48. Chiannilkulchai N, Ammoury N, Caillou B, Devissaguet JP, Couvreur P, (1990) Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemother Pharmaco l26: 122-126.
49. Verdun C, Brasseur F, Vranckx H, Couvreur P, Roland M, (1990) Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer Chemother Pharmacol 26: 13-18.
50. Alhareth K, Vauthier C, Bourasset F, Gueutin C, Ponchel G, et al. (2012) Conformation of surface-decorating dextran chains affects the pharmacokinetics and biodistribution of doxorubicin-loaded nanoparticles. Eur J Pharm Biopharm 81 (2):: 453-7.
51. Zara GP, Cavalli R, Fundarò A, Bargoni A, Caputo O, et al. (1999) Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol Res 40 (3):: 281-6.
52. Ayen WY, Kumar N, (2012) In Vivo Evaluation of Doxorubicin-Loaded (PEG)(3)-PLA Nanopolymersomes (PolyDoxSome) Using DMBA-Induced Mammary Carcinoma Rat Model and Comparison with Marketed LipoDox™. Pharm Res PMID pp. 22669705.
53. Li X, Ding L, Xu Y, Wang Y, Ping Q, (2009) Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm 373 (1-2):: 116-23.